GCP
CRBU icon

Gill Capital Partners’s Caribou Biosciences CRBU Stock Holding History

Gill Capital Partners’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132 Hold
75
– – ﹤0.01% 677
2026
Q1 		$143 Buy
+75
New +$129 ﹤0.01% 668

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Gill Capital Partners's CRBU Position: Q2 2026 in Review

Gill Capital Partners held its Caribou Biosciences (CRBU) position steady in Q2 2026 at 75 shares worth $132. The position accounts for ﹤0.01% of the portfolio, ranked #677.

Gill Capital Partners first reported a position in CRBU in Q1 2026 and has held it in 2 quarters since. The position peaked at $143 in Q1 2026. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Gill Capital Partners held 75 shares of Caribou Biosciences worth $132 as of Q2 2026.
  • Gill Capital Partners left its Caribou Biosciences share count unchanged in Q2 2026.
  • Caribou Biosciences made up ﹤0.01% of Gill Capital Partners's portfolio in Q2 2026, its #677 holding.
  • Gill Capital Partners first reported a position in Caribou Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Gill Capital Partners's Caribou Biosciences position peaked at $143 in Q1 2026.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Gill Capital Partners's 13F filing for Q2 2026, filed 20 Aug 2026.